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The major immediate-early gene of human cytomegalovirus encodes several isoforms of an immediate-early
protein which has distinct transcriptional regulatory properties. The IE86 isoform autorepresses the major
immediate-early promoter by directly binding the cis repression signal element located between the TATA box
and the mRNA cap site. In addition to this activity, IE86 stimulates other viral and cellular promoters. One
mechanism by which eukaryotic regulatory proteins are thought to stimulate transcription is by contacting one
or more general transcription factors. We show that the IE86 protein physically interacts with the DNA-binding
subunit (TATA-binding protein) human transcription factor IID via the TATA-binding protein-contacting
domain in the N terminus of IE86. In a mobility shift assay, IE86 was also observed to stabilize the binding of
TATA-binding protein to promoter DNA. The domains within IE86 responsible for mediating transactivation
and repression functioned independently. These experiments thus demonstrate the elegant ability of human
cytomegalovirus to join different protein domains to produce distinct multifunctional proteins.
The immediate-early (IE) genes of human cytomegalovirus
(HCMV) encode transcriptional regulatory factors which, to-
gether with host cell proteins, temporally regulate subsequent
viral gene expression (4, 10, 40, 41, 43-45, 47). We are
interested in understanding the role of viral and cellular
proteins involved in coordinating RNA polymerase II activity
associated with HCMV gene regulation.
Three predominant IE protein isoforms originate from an
abundant region of IE expression which is controlled by the
major IE promoter (MIEP) (5, 42, 44, 45). These isoforms are
generally distinguished by their apparent molecular masses of
72 (IE72), 86 (IE86), and 55 (IE55) kDa. Since these IE
protein isoforms are all derived from a single precursor mRNA
by differential splicing and polyadenylation site usage, the virus
can join various domains to create proteins with similar and
distinct functions. Recently, IE86 was shown bind the cis
repression signal (crs) element located between the TATA box
and the mRNA cap site of the MIEP (21, 24). The IE86
protein possesses a domain between amino acid residues 365
and 519 which contains a putative zinc finger and a leucine-rich
region (Fig. IB) that was shown to be critical for this interac-
tion (21, 32). The crs element is responsible for conferring
negative repression on the MIEP by IE86 (7, 16, 30, 36, 38).
Although IE86 and the TATA-binding protein (TBP) were
observed to bind DNA simultaneously, binding of one protein
impaired the binding of the other (21). Although IE86 may
effect the binding of transcription factor IID (TFIID), the
multisubunit complex containing TBP, to the crs element, the
main block in transcription is likely at the level of TFIIB
recruitment (21). The IE55 protein, however, lacks the domain
in IE86 between amino acid residues 365 and 519 and conse-
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quently is unable to bind the crs element and repress MIEP
activity (1, 21). Therefore, IE55, like IE72, which also does not
possess this domain, is a transactivator rather than a repressor
of MIEP activity (1, 8, 16, 39). By contrast, IE86, IE55, and
IE72 are all capable of transactivating heterologous promoters
(1, 10, 14, 17, 20, 43, 48, 49). Together, the IE86 and IE72
proteins synergistically transactivate different kinetic classes of
HCMV promoters as well as other viral and cellular promoters
(9, 14, 17, 43, 47-49). Thus, the relative levels of these proteins
may be critical for determining the outcome of viral infection.
The mechanisms by which the IE proteins interact with host
proteins to coordinate viral transcription are not clearly un-
derstood. Evidence from studies on other viral IE proteins
suggest that the HCMV IE proteins may interact with basal or
sequence-specific transcription factors or by direct binding to
DNA. For example, the large adenovirus EIA protein binds
both the sequence-specific transcription factor ATF-2 and
TBP, from which it was suggested that EIA stimulated tran-
scription through TBP after recruitment to the promoter by
ATF-2 (19, 26, 31). The Zta (ZEBRA, EBI, or BZLFI)
protein from Epstein-Barr virus binds a DNA motif upstream
of the target promoter and appears to stimulate transcription
by stabilizing the binding of TBP to DNA (27).
Recently, IE86 was shown to transactivate an early HCMV
promoter in nuclear extracts prepared from U373-MG, HeLa,
and Drosophila embryo cells (23). These Drosophila embryo
nuclear extracts contained relatively small amounts of nonspe-
cific DNA-binding proteins. Addition of histone Hl to these
extracts resulted in greater transactivation of this early pro-
moter by IE86, suggesting that activation by IE86 involves
antirepression (23). In addition, IE86 has also been shown to
interact directly with TBP by coimmunoprecipitation and
Western blot (immunoblot) analysis in the absence of DNA
(15). However, the conformation adopted by TBP in these
studies is likely different from that adopted when TBP is bound
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FIG. 1. Wild-type and mutant forms of IE86 and
Coomassie-stained gel showing the wild-type and
IE86 after nickel chelate chromatography and di
fractions containing purified protein. Lane 1, wild-typ
8, mutant forms IE86AN6AC2, IE86AMS, IE86
IE86AC2, IE86AN6, and IE86AN1, respectively. (B)
sentation of the HCMV IE86 protein. The three am
are indicated by the shaded regions between amino a(
The zinc finger (Zn) acidic region, represented by t
between amino acids 551 and 579, the six-histidine ta
restriction sites used in the construction of the exprn
also shown. (C) Schematic representations of wild-
IE86 proteins. The amino acids expressed, togetl
histidine tag and initial ATG codon, are indicated.
to DNA (22, 34). In addition, an IE86-gluta
ferase fusion protein was used to coprecipii
crude nuclear extracts of human embryonic
These studies indicate the significance of this in
more physiological conditions. Therefore, ther
ble mechanisms which IE86 may stimulate tran
ysis of the domains responsible for these intera
for the elucidation of IE86 function.
We have examined the ability of a panel of
IE86 proteins to interact with purified human
that a specific domain in the N terminus of IE
sible for binding TBP. Moreover, the N-te
bound TBP in the absence of the domain
repression, demonstrating their independence
tile nature of a virus that is able to join
domains.
MATERIALS AND METHODS
Plasmid constructions. The expression pl;
AN6 was constructed by digesting p86,6His (
filling in the ends with Klenow polymerase, ligating 8-bp
BamHI linkers (New England Biolabs, Beverly, Mass.), and
digesting with BamHI. The fragment released was subcloned
back into the BamHI-digested p86,6His vector, and the sense
orientation was selected. Plasmid p86,6HisAN6AC2 was gen-
erated by digesting p86,6HisAXN6 with StuI and Hind!!!, filling
in the ends with Klenow polymerase, and ligating them back
together. The Hind!!! site and sequence immediately down-
stream encodes stop codons in all three reading frames.
Plasmid p86,6HisAMS was constructed by digesting p86,6His
with Sac! and MluI, treating the ends with mung bean exonu-
clease, and ligating them back together. The remaining plas-
mids expressing mutant forms of IE86 were described previ-
ously (21). The truncated form of TBP (TBPANl) was
generated by digesting phTBP,6His (21) with Pstl and PmlI.
The annealed oligonucleotides 5'-GTGGCAGTGGCAGCT
GCA-3' and 5'-GCTGCCACTGCCAC-3', which had PmlI-
Amino Acids and Pstl-compatible ends, respectively, were subsequently in-
Expressed serted to juxtapose Val-97 (GCA) of full-length TBP with the
1 1-579 six-histidine tag. All cloning steps were confirmed by direct
154-541 sequencing of the plasmid DNA.
] 1141/154-579 Purification of recombinant proteins. Purification of the
IE86 and TBP recombinant proteins has been described
] 1-579 previously (21). Briefly, Escherichia coli strains harboring each
of the expression plasmids were grown to an optical density at1-15S3 550 nm of 0.7 to 0.8 before induction with 200 ,ug of isopropyl-
1-541 ,B-D-thiogalactopyranoside (IPTG) per ml. Cells were har-
i1 5 4-5 7g vested after 90 to 120 min and lysed in buffer containing 50] mM sodium phosphate (pH 7.8), 1 mM phenylmethylsulfonyl
humaTBP(A)
fluoride (PMSF), 1% Tween 20, 1 M NaCl, and 1 mg ofhuman TBP. (A) lysozyme per ml for 20 min prior to sonication. After centrif-
alysis of pooled ugation, the cleared lysate was subjected to Ni2I chelate
me IE86 lanes 2 to chromatography (Qiagen, Chatsworth, Calif.) over a column
mZn, 1E86tvC1 equilibrated in buffer containing 50 mM sodium phosphate
Schematic repre (pH 7.8), 500 mM NaCl, and 10% glycerol. After the column
phipathic helices was washed, fractions were eluted in the same buffer contain-
cids -30 and 105. ing 500 mM imidazol at pH 6.0. Fractions containing each of
'he shaded region the proteins were pooled and dialyzed against either 50 mM
ig (6His), and the sodium phosphate (pH 7.6)-250 mM NaCl-1 mM 3-mercap-
ession vectors are toethanol-30% glycerol or 20 mM HEPES (hydroxyethylpipera-
-type and mutant zine-N'-2-ethanesulfonic acid, pH 8.0)-0.5 mM EDTA-2 mM
her with the six- MgCl2-l mM ,B-mercaptoethanol-50 mM KCl-30% glycerol for
the HCMV IE proteins and human TBP, respectively. Purified
proteins were analyzed on 12% polyacrylamide-sodium dodecyl
sulfate (SDS) gels and stained with Coomassie blue; concentra-
tthione-S-trans- tions were then determined by the Bradford method.tate TBP from Mobility shift assay. The mobility shift assay was performed
lung cells (12). essentially as described previously (13) except that the assay
teraction under buffer contained 25 mM Tris-HCl (pH 8.0), 0.5 mM dithio-
e are two possl- threitol, 0.5 mM EDTA, 6.25 mM MgCI2, 0.2 ,ug of poly(dG:iscrption. Anal- dC), 10% glycerol, and cold competitor oligonucleotides astctions is critical indicated, in a total volume of 25 [l. Probe PPM1 consisted of
oligonucleotides 5'-AGCTTCATTGGGGAGGTCTATATA
purified mutant AGCAGAGCT-3' and 5'-AGCTCTGCTTATATAGACCTC
TBP. We found CCCAATGAAGCT-3', which contained the HCMV MIEP
£86 was respon- TATA box but only part of the crs element. The wild-type and
rminal domain mutant forms of IE86 were incubated for 2 min in assay buffer
responsible for before the addition of 0.5 pmol of probe which had been
and the versa- labeled with Sequenase (USB) and [c_-32P]dATP. The incuba-
various protein tion was continued for 10 min before the mix was loaded onto
a 4% polyacrylamide gel. Assay mixes which contained anti-
body were incubated for 2 min after the addition of probe
before the addition of antibody. Incubation of these assay
mixes was then continued for a further 10 min. Monoclonal
asmid p86,6His antibodies to IE86 which recognized epitopes between amino
21) with MluI, acid residues I and 47 and 47 and 153 were raised in mice with
J. VIROL.
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FIG. 2. Mobility shift assay demonstrating the interaction of IE86 with TBP on promoter DNA. All lanes in both panels contained 0.5 pmol
of the PPM1 probe. (A) Lanes 2 to 4 and 9 to 11 also contained 50 nM human TBP, and lanes S to 7 contained an N-terminal truncation of TBP
(TBPAN1), as indicated by a +. BSA (500 pLM) was included in lanes 1 to 7 to help stabilize the binding of TBP. The presence of BSA was not
observed to effect the migration pattern of TBP. In addition, lanes 3 and 6 and lanes 4 and 7 contained a 15-fold excess of unlabeled PPM1 and
5'-JTGTGTAGGCCACGTGACCGGGT-3' (encompassing a USF binding site), respectively. Lanes 10 and 11 also included 125 nM IE86 (86*)
and 250 nM IE86 (86), respectively. The monomeric (complex I) and dimeric (complex II) forms of promoter-bound wild-type TBP and mutant
TBPAN1 are indicated. (B) Lanes 2 to 5 included 50 nM human TBP, and lanes 5 to 7 also included 250 nM IE86. Monoclonal antibodies to IE86
(epitope between residues 1 and 47), (lanes 3 and 6) and to gpl20 of human immunodeficiency virus (lanes 4 and 7) were also present in the assay
at a concentration of 40 jxg/ml. The positions of the TBP-IE86 (TBP:86) and the TBP-IE86-antibody (TBP:86:Ab) nucleoprotein complexes are
also indicated, together with the origin of the gel and the free probe.
purified IE86 as the antigen (20a). The gel and running buffer
contained 6.7 mM Tris-HCI (pH 7.3), 3.3 mM sodium acetate,
and 1 mM EDTA. After electrophoresis, the gel was dried and
autoradiographed.
RESULTS
IE86 physically interacts with and promotes binding of TBP
to DNA. Recombinant IE86 and TBP were expressed in and
purified from E. coli as described in Materials and Methods.
Purification was facilitated by the introduction of a short linker
sequence encoding six histidine residues at the 5' end of each
cDNA. The six-histidine tag allowed the protein to be purified
by nickel chelate chromatography. After purification, both
IE86 and TBP were observed to be approximately 90%
homogeneous (Fig. 1A, lane 1, and data not shown, respec-
tively). The interaction of TBP with a fragment of the MIEP
from -43 to -19 (PPM1) was examined in a mobility shift
assay (Fig. 2A, lane 2). The inclusion of bovine serum albumin
(BSA; 500 ,uM) in the reaction buffer helped to stabilize the
binding of TBP to DNA (Fig. 2A, compare lanes 2 and 8), as
demonstrated previously (27). Two complexes containing TBP,
which correspond to the monomeric and dimeric forms of TBP
(TBP I and II, respectively) bound to DNA, as described
previously (22). Inclusion of BSA did not affect the migration
pattern of the monomeric or dimeric forms of TBP.
Competition experiments demonstrated the specificity of
these complexes (Fig. 2A, lanes 3 and 4). Excess unlabeled
PPM1 probe competed for the binding of labeled probe to
TBP (Fig. 2A, lane 3), whereas excess unlabeled probe con-
taining a USF binding site did not (Fig. 2A, lane 4). Similar
experiments were performed with a deletion mutant of TBP
(Fig. 2A, lanes 5 to 7). This protein, TBPAN1, was composed
of amino acids residues 97 to 357 of wild-type TBP. This
protein also yielded two complexes (TBPAN1 I and II) which
migrated with a faster mobility than wild-type TBP because of
the loss of 96 N-terminal amino acids (Fig. 2A, compare lanes
5 and 2). The competition experiments shown in Fig. 2A, lanes
6 and 7, demonstrate the specificity of the TBPAN1 nucleo-
protein complexes. Unlabeled excess PPM1 competed for
binding, whereas the probe containing the USF binding site did
not compete for binding to TBPAN1. Identical results were
obtained with TBP lacking the six-histidine tag (data not
shown).
The PPM1 probe contained a small amount of the sequence
between -24 and -19 that was previously shown to be
protected by IE86 during DNase I digestion (21, 24). However,
the IE86 protein was not observed to bind this probe directly
(data not shown). On this short exposure, binding of TBP to
DNA was not readily visible (Fig. 2A, lane 9) and had to be
stabilized by the inclusion of BSA to be observed (Fig. 2A, lane
2). By contrast, a more dramatic stabilization of the TBP II
nucleoprotein complex was observed in the presence of 125
nM IE86 (Fig. 2A, lane 10). Since little of the TBP I nucleo-
protein complex remained, the effect of IE86 was a preferential
stabilization of the TBP II complex, a phenomenon not
observed with BSA (Fig. 2A, compare lanes 2 and 10).
Addition of 250 nM IE86, however, was required to form a
stable IE86-TBP nucleoprotein complex of slower mobility
(Fig. 2A, lane 11). Titration of IE86 into the reaction mix at
concentrations between 125 and 250 nM resulted in a gradual
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FIG. 3. Interaction of mutant forms of IE86 with TBP. All lanes
contained 0.5 pmol of the PPM1 probe and 50 nM human TBP except
lane 1, as indicated. In addition, 125 nM (odd-numbered lanes) and
250 nM (even-numbered lanes) of IE86, IE86/C2, IE86AN6,
IE86zAN1, IE86AC1, and IE86AN6AC2 were used. The positions of the
nucleoprotein complexes corresponding to TBP and TBP-IE86 (TBP:
86) are indicated. The mutant IE86-TBP nucleoprotein complexes
were observed to migrate between the TBP and wild-type IE86-TBP
complexes because of their smaller size. The positions of the origin and
the free probe are also indicated.
increase in the amount of supershifted versus stabilized TBP
(data not shown).
To demonstrate that IE86 is a part of the IE86-TBP
nucleoprotein complex, a monoclonal antibody that recognized
an epitope between amino acid residues 1 and 47 of IE86 was
included in the assay. This monoclonal antibody supershifted
the reaction containing 250 nM IE86 and 50 nM TBP together
with probe (Fig. 2B, compare lanes 5 and 6). By contrast, a
supershift was not observed with a control antibody which
recognized the gpl2O envelope protein of human immunode-
ficiency virus (Fig. 2B, lane 7). Addition of either antibody to
the assay in the absence of IE86 did not supershift the TBP
nucleoprotein complex (Fig. 2B, lanes 3 and 4). In addition, a
monoclonal antibody to human TBP was also capable of
supershifting the TBP and TBP-IE86 nucleoprotein complexes
(51). A minor stabilization of the two TBP nucleoprotein
complexes was also observed in the presence of antibody (Fig.
2B, lanes 3 and 4). These complexes migrated below that of the
stable IE86-TBP complex (Fig. 2B, lane 5). These data show
that IE86 is present within the shifted IE86-TBP nucleoprotein
complex and demonstrate that IE86 interacts with TBP bound
to promoter DNA.
Interaction of mutant IE86 proteins with TBP and identifi-
cation of the TCD. To delineate the domain in IE86 responsi-
ble for binding TBP, various mutant IE86 expression plasmids
were constructed. After their expression in E. coli, all of the
proteins were purified and resolved on polyacrylamide gels
(Fig. IA, lanes 2 to 8). These mutant forms of IE86 are also
schematically represented in Fig. IC. The IE86AC2 mutant,
which lacks the extreme C-terminal acidic domain of IE86
(amino acids 542 to 579), showed the same ability to bind TBP
FIG. 4. Interaction of mutant forms of IE86 with a truncated form
of TBP consisting of the conserved C-terminal domain. All lanes
contained 0.5 pmol of the PPM1 probe and 50 nM human TBPANI
(except lane 1), as well as indicated. IE86, IE86AC2, IE86AN6,
IE86ANI, IE86ACI, and IE86zAN6AC2 at 125 nM (odd-numbered
lanes) or 250 nM (even-numbered lanes). The positions of the origin
and the free probe are also indicated.
as wild-type IE86, demonstrating that this region is not respon-
sible for contacting TBP (Fig. 3, lanes 5 and 6). The IE86AC2-
TBP complex migrated slightly faster than the wild-type IE86-
TBP nucleoprotein complex because of the removal of the
C-terminal acidic region (Fig. 3, compare lanes 6 and 4).
Further truncation of amino acid residues from the C-terminal
end yielded the IE86AC1 mutant (Fig. IC, construct 5). This
protein was also observed to stabilize and shift the TBP
nucleoprotein complex (Fig. 3, lanes 11 and 12). The difference
in the migration of the TBP and TBP-IE86AC1 nucleoprotein
complexes, however, was marginal, because the IE86ACI
protein consisted only of amino acid residues I to 153 of
wild-type IE86. Nevertheless, this indicates that the domain of
IE86 responsible for interacting with promoter-bound TBP is
present within the N terminus.
To confirm these results, two mutant forms of IE86 were
produced with deletions in the N terminus (Fig. IC, constructs
7 and 8). Removal of amino acids 1 to 46 of IE86 resulted in
protein IE86AN1 (Fig. IC, construct 7), which was still able to
interact with TBP (Fig. 3, lanes 9 and 10). Further truncation
of the N terminus of IE86 generated the mutant IE86zXN6 (Fig.
IC, construct 8), which was unable to form a stable complex
with TBP prebound to DNA (Fig. 3, lane 8). These data
demonstrate that the TBP-contacting domain (TCD) is located
between amino acid residues 47 and 153 of IE86. Since both N-
and C-terminal mutant IE86 proteins stabilized TBP binding,
more than one domain in IE86 may be responsible for this
activity.
Comparison of TBPs from several different species revealed
a variable N-terminal domain as well as a highly conserved
C-terminal domain (34). The conserved C-terminal domain is
composed of two direct repeat sequences separated by a basic
region (18). All transcription-regulatory proteins examined,
including IE86, have been shown to contact TBP via the
conserved domain and not the variable N-terminal domain (3,
15, 25, 26). To obtain better resolution of the mutant IE86-
TBP nucleoprotein complexes, the TBPANI mutant, which
lacks 96 N-terminal amino acids, was used in the mobility shift
assay. The conserved domain of TBP was also shifted by
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FIG. 5. Supershift of the mutant IE86-TBP nucleoprotein com-
plexes by monoclonal antibody recognizing residues 47 to 153 of IE86.
All lanes contained 0.5 pmol of PPM1 probe and 50 nM human TBP
(except lane 1), as indicated. Lane 3 also contained 125 nM IE86 (86*).
Lanes 4 to 13 all contained a 250 nM concentration of either wild-type
or mutant forms of IE86, as indicated. Monoclonal antibody to
residues 47 to 153 of IE86 was included in lanes 5, 7, 9, 11, and 13, as
indicated, at a concentration of 200 ,ug/ml. The origin and position of
the free probe are shown.
wild-type IE86 protein (Fig. 4, compare lanes 3 and 4). The
mutant forms of IE86 which were able to form a stable
complex with wild-type TBP were also able to interact with the
truncated TBP (Fig. 4). Since mutant TBP migrated faster than
wild-type protein, the stable TBPAN1-IE86AC1 nucleoprotein
complex was more clearly resolved from the complex contain-
ing just TBP and probe (Fig. 4, compare lanes 11 and 12). In
addition, neither the IE86AN6 nor the IE86AN6AC2 protein
was able to interact with the conserved domain of TBP (Fig. 4,
lanes 8 and 14).
To conclusively demonstrate that the various mutant forms
of IE86 stably interact with TBP, each of the mutant IE86-TBP
nucleoprotein complexes was incubated with a monoclonal
antibody which recognized an epitope in IE86 between amino
acid residues 47 and 153. An identical supershift of the
wild-type IE86-TBP nucleoprotein complex was obtained with
this monoclonal antibody (Fig. 5, lane 5) as with the monoclo-
nal antibody used in Fig. 2B, which recognized an epitope in
IE86 between amino acid residues 1 and 47. In addition, the
IE86AN1-TBP, IE86AC2-TBP, and IE86zvC1-TBP complexes
were also supershifted with the antibody against residues 47 to
153 (Fig. 5, lanes 9, 11, and 13, respectively). By contrast, this
antibody did not supershift the control reaction containing
IE86AN6, TBP, and probe (Fig. 5, lane 7). Also, a monoclonal
antibody which recognized the mutant IE86AMS protein failed
to develop a supershift in the presence of this protein, TBP,
and probe, indicating that although IE86AMS was able to
86 Ab Control Ab
86 AMS mZnflProtein - - ,fi + *Xv
TBP - + + + + + + + + + + + + +
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Origin- -__ so * *-a s
Free
Probe
FIG. 6. Independence of the domains responsible for repression
and activation. Mobility shift analysis of the interaction of IE86mZn
and IE86AMS with TBP. All lanes contain the PPMI probe (0.5 pmol)
and 50 nM TBP where indicated (+). Lanes 3, 5, and 7 and 4, 6, and
8 contained 125 and 250 nM of IE86, IE86AMS, or IE86mZn (mZn),
respectively. Probe was incubated with 250 nM IE86 (lanes 9 and 12),
IE86AMS (lanes 10 and 13), and IE86mZn (lanes II and 14). In
addition, monoclonal antibody (40 ,ug/ml) to the IE86 (residues 1 to
47) epitope or the control antibody to gpl20 from human immunod-
eficiency virus was included in lanes 9 to 11 and 12 to 14, respectively.
The origin and position of the free probe are indicated.
stabilize the TBP II complex, it was not present within the
complex (Fig. 6A, lane 10; see below for details). Also, the
IE86-stabilized TBP II complex had the same mobility as the
TBP II complex in the absence of IE86 (Fig. 2A, compare lanes
2 and 10). Together, these data demonstrate that the TCD is
present within the N terminus of IE86.
TBP-binding and repression properties of IE86 function
independently. We have shown that a mutation in the putative
zinc finger of IE86 which prevented IE86 from binding the crs
element converted the protein from a repressor to an activator
of MIEP activity in vivo (21). The zinc finger mutant of IE86,
like wild-type IE86, was observed to bind to and shift the TBP
nucleoprotein complex, consistent with previous findings (Fig.
6, compare lane 8 with lane 4). The IE86-TBP and IE86mZn-
TBP complexes were both supershifted with the IE86 (residues
I to 46) antibody (Fig. 6, lanes 9 and 11, respectively) but not
with the control antibody (Fig. 6, lanes 12 and 14, respectively).
To more closely map the domain in IE86 which contacts TBP,
a mutant of IE86 containing a small internal deletion was
expressed in and purified from E. coli. This mutant, IE86AMS,
contained a deletion of 12 amino acids between amino acid
residues 141 and 154 of IE86. This mutant was not observed to
shift the TBP nucleoprotein complex (Fig. 6, lane 6). In
addition, when either the IE86 (residues 1 to 47) or the control
antibody was included in the assay with IE86AMS, supershift
of the TBP nucleoprotein complex was not observed (Fig. 6,
lane 13). Therefore, the ability of IE86 to bind to TBP on DNA
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is independent of its ability to interact directly with DNA via
the putative zinc finger domain.
DISCUSSION
In this study, the HCMV IE86 protein was shown to interact
with TBP on promoter DNA. In addition, the presence of IE86
stabilized the binding of TBP to the TATA box, which may also
contribute to the ability of this protein to stimulate transcrip-
tion. Mutagenesis of the IE86 protein revealed that deletion of
amino acids 1 to 153 but not I to 47 in the N terminus of IE86
disrupted the ability of IE86 to bind promoter-bound TBP. In
addition, a smaller internal deletion of the amino acids be-
tween 141 and 154 of IE86 also disrupted the IE86-TBP
interaction. The conformational integrity of the internal dele-
tion mutant was assessed by demonstrating that this protein
was still capable of mediating repression of the MIEP via
domains within the C terminus (data not shown). The TCD
therefore represents the first identification of a module in the
IE proteins responsible for interacting directly with a cellular
transcription factor. Removal of the TCD did not interfere
with the ability of IE86 to enhance TBP II binding to promoter
DNA. This observation suggests that an additional domain(s)
within IE86, not identified in this study, might be involved in
interacting with TBP. Such an interaction domain may require
only a transient association with TBP and/or may occur in
solution before TBP binds the TATA element. The TCD of
IE86 was also shown to be critical for the ability of IE86 to
activatc transcription in vivo but was not involved in autore-
pression of the MIEP (data not shown). A mutant of IE86
carrying a mutation within the putative zinc finger module that
failed to autorepress but instead enhanced transcription in vivo
(21) was still capable of binding TBP. Therefore, this pleiotro-
pic viral IE protein has two independent mechanisms by which
it can recognize and influence a specific promoter. These two
independent mechanisms involve distinct modules of the IE86
protein that recognize promoter DNA either by tethering IE86
to a DNA-bound protein or by mediating the direct interaction
of IE86 with DNA.
Human TBP exists in vivo as a multiprotein complex
(TFIID) in which the central DNA-binding subunit, TBP, is
complexed with a variety of other polypeptides, known as
TBP-associated factors (6, 11, 35). Recently, the interaction of
IE86 with TFIID in vivo has been indicated by the ability of an
IE86-glutathione-S-transferase fusion protein to coprecipitate
TBP from crude nuclear extracts (12). The binding of IE86 to
the C terminus of TBP fused to glutathione-S-transferase was
also demonstrated by coimmunoprecipitation and Western
blot analysis (15). In addition, an IE86-glutathione-S-trans-
ferase fusion protein was shown to transactivate an early
HCMV promoter in vitro. After incubation of this promoter
with histone HI, IE86-glutathione-S-transferase was observed
to alleviate histone HI-induced repression of basal transcrip-
tion (23). Whether IE86 counteracted the effect of histone HI
by a direct interaction or by enhancing the recruitment of RNA
polymerase II via interaction with TBP without being impeded
by histone HI-induced repression is unknown. The latter
mechanism is similar to that suggested for the transcription
factor USF (50). The TCD domain also encompasses a nuclear
localization signal (37), suggesting that this domain may inter-
act with additional factors and indicating the multifunctional
role of this module. However, the extent to which the TCD and
nuclear localization signal overlap is not known.
Interestingly, Klucher et al. also demonstrated that a mutant
IE86-glutathione-S-transferase protein which lacked the C-
terminal acidic domain and is thus comparable to IE86AC2
was unable to stimulate transcription from an early promoter
in vitro (23). A mutant with a similar truncation of the IE86
protein was also observed to be incapable of transactivating a
herpes simplex virus type 2 early promoter in vivo (38).
Therefore, domains other than the TCD are also required by
IE86 to activate transcription. Thus, one mechanism by which
IE86 may stimulate transcription is by acting as a bridging
molecule between the general transcription machinery and
another factor(s), represented in this case by an upstream
activator protein.
By homology to other proteins, the N termini of 1E86, IE55,
and IE72 all contain three helices (Fig. IB). Part of H3 in IE86
is encoded by exon 3, and the remainder is encoded by exon 5
(Fig. 1). From our mapping studies, the TCD in IE86 is located
just downstream of this putative motif in a previously unde-
fined region of the protein. Although IE72 contains a putative
helix spanning exons 3 and 4, it does not contain the TCD
present in IE86. Therefore, these data correlate with the
finding that a stable IE72-TBP interaction was not observed in
coimmunoprecipitation and Western blot studies (15).
Previous mapping studies with genomic DNA fragments
have found that a variety of elements within IE86 are essential
for repression and/or activation in vivo (17, 33, 36, 37, 43).
However, since multiple proteins were expressed in these
transfection assays, mutation of IE86 in these studies may have
indirectly affected the function of or been compensated for by
one of the other regulatory proteins expressed from this
region. Therefore, these studies can only serve as a reference
to direct the mapping of IE86 interactions in a more defined
system.
Other viral proteins also possess domains which have been
shown to contact TBP. The transcriptional activator VP16 of
herpes simplex virus type 1 was shown to intcract with yeast
TBP and TFIIB (29, 46). However, experiments designed to
dissect the mechanism of VP16 action revealed that VP16
stabilized the binding of TFIIB to template DNA but had little
effect on the binding of TBP (29). By contrast, the Zta protein
from Epstein-Barr virus was shown to stabilize TBP binding to
the TATA box via a direct physical interaction (27). In our
studies, IE86 also stabilized the binding of TBP to template
DNA, although the mechanism was independent of the TCD.
The adenovirus EIA and the IE86 proteins contain domains
responsible for repression as well as activation (2, 26, 28). EIA
(26) and the specific upstream DNA-binding protein ATF-2
(31) were shown to contact TBP and thus may function as
bridging molecules, as we have proposed for IE86 (Fig. 6).
Moreover, the activation and repression domains of EIA, like
those in IE86, were shown to function independently, although
the activation domain was dominant over the repression
domain in EIA (28). These analyses show that viral regulatory
proteins have adopted a number of common themes to coor-
dinate their expression. Moreover, the mechanisms by which
these proteins interact with those of the host frequently
parallel host protein-host protein interactions. Thus, further
investigation of the regulatory mechanisms of the HCMV IE
proteins should add to our understanding of both viral and
cellular gene regulation.
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